Molecular Approaches to Cancer Immunotherapy

November 7-11, 1993
The Grove Park Inn, Asheville, North Carolina

CONFERENCE CHAIRPERSON
Ralph A. Reisfeld / La Jolla, CA

SCIENTIFIC PROGRAM

Keynote Address
Giorgio Trinchieri / Philadelphia, PA

Monoclonal Antibodies for Tumor Therapy
Alan N. Houghton / New York, NY
Albert F. LoBuglio / Birmingham, AL
Ira Pastan / Bethesda, MD
David A. Scheinberg / New York, NY

Genetically Engineered Antibodies
Stephen D. Gillies / Lexington, MA
Jeffrey Schlom / Bethesda, MD
Richard P. Junghans / Boston, MA
Sherie L. Morrison / Los Angeles, CA
Clive Woodhouse / Mountain View, CA

Gene Therapy of Cancer
James J. Mulé / Palo Alto, CA
Drew M. Pardoll / Baltimore, MD
David T. Curtel / Chapel Hill, NC
Patrick Hwu / Bethesda, MD
Elizabeth Jaffee / Baltimore, MD

Cytokines in Tumor Therapy
Steven Gillis / Seattle, WA
Roland Mertelsmann / Freiburg, Germany
Ronald Levy / Stanford, CA
Terry Strom / Boston, MA

Tumor Antigens Recognized by T-Cells
Olivera J. Finn / Pittsburgh, PA
Per A. Peterson / La Jolla, CA
Martin A. Cheever / Seattle, WA
Michael T. Lotze / Pittsburgh, PA

Antibodies as Immunogens
Soldano Ferrone / Valhalla, NY
Dorothée Herlyn / Philadelphia, PA
Kenneth Foon / Lexington, KY
Alan N. Houghton / New York, NY

Future of Cancer Immunotherapy
Isaiah J. Fidler / Houston, TX
Paul M. Sondel / Madison, WI
Irwin D. Bernstein / Seattle, WA
Eugenie S. Kleinerman / Houston, TX

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

215-440-9300  215-440-9313 (FAX)
AMERICAN ASSOCIATION FOR CANCER RESEARCH
SCIENTIFIC CONFERENCES: 1993-1994

OCTOBER 17-21, 1993
Cell Death and Cancer
Chairperson: Alan R. Eastman, Hanover, NH
Chatham Bars Inn, Chatham (Cape Cod), MA

NOVEMBER 7-11, 1993
Molecular Approaches to Cancer Immunotherapy
Chairperson: Ralph A. Reisfeld, San Diego, CA
Grove Park Inn, Asheville, NC

NOVEMBER 9-13, 1993
Interactions of Cancer Susceptibility Genes and Environmental Carcinogens
Joint Meeting with International Agency for Research on Cancer (IARC)
Chairperson: Frederick P. Li, Boston, MA, and Ruggero Montesano, Lyon, France
IARC, Lyon, France

DECEMBER 5-9, 1993
Cell Signalling and Cancer Treatment
Joint Meeting with British Association for Cancer Research and European Organisation for Research and Treatment of Cancer (PAM Group)
Chairpersons: Garth Powis, Tucson, AZ; Paul Workman, Glasgow, Scotland
El San Juan Hotel, San Juan, PR

JANUARY 17-22, 1994
Risk Assessment in Environmental Carcinogenesis
Co-Sponsored by the Environmental Mutagen Society
Chairpersons: Philip C. Hanawalt, Stanford, CA; James A. Swenberg, Chapel Hill, NC
Whistler Resort and Conference Center, Whistler, B.C., Canada

JANUARY 31-FEBRUARY 5, 1994
Molecular Genetics of Progression and Metastasis
Chairperson: Lance A. Liotta, Bethesda, MD
Big Sky Resort, Big Sky, MT

FEBRUARY 19-24, 1994
Cancer: Perturbation in Cell Cycle Control and Genomic Integrity
Chairpersons: Thea D. Tlsty, Chapel Hill, NC; Lawrence A. Loeb, Seattle, WA
Banff Springs Hotel, Banff, Alberta, Canada

MARCH 5-11, 1994
Growth Factors, Development, and Cancer
Joint Meeting with Friedrich-Miescher Institut
Chairpersons: Harold L. Moses, Nashville, TN; Bernd Groner, Basel, Switzerland
Congress Center, Interlaken, Switzerland

APRIL 10-13, 1994
85th Annual Meeting
Chairperson: Karen S. H. Antman, Boston, MA
Moscone Convention Center, San Francisco, CA

OCTOBER 16-20, 1994
Transcriptional Regulation in Differentiation (Tentative Title)
Chairpersons: Eric N. Olson, Houston, TX; Bruce M. Spiegelman, Boston, MA
Chatham Bars Inn, Chatham (Cape Cod), MA

AACR members will receive brochures on the above special conferences as soon as they are available. Nonmembers should call or write:

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
This issue’s cover features the first Clinical Directors of the National Cancer Institute (NCI), Bethesda, MD, early pioneers who played leading roles in the development of intramural and extramural programs of the NCI during a period of rapid advances. They were recruited by NCI Scientific Director G. Burroughs Mider shortly after the opening of the Clinical Center on the Bethesda campus in 1953. First came C. Gordon Zubrod (upper left), in 1954, as Chief of the NCI’s General Medicine Branch and Clinical Director, ultimately rising to Director, Division of Cancer Treatment, in 1972. Dr. Zubrod was a graduate of the College of Physicians and Surgeons of Columbia University; he interned at Presbyterian Hospital, New York, NY, with service in the Army during World War II and positions at Johns Hopkins and St. Louis Universities prior to his NCI appointment. Nathaniel I. Berlin (center) was recruited in 1956. He received the M.D. degree from SUNY-Downstate and a Ph.D. from the University of California. He was a postdoctoral fellow at the University of California, Berkeley, and at the National Institute for Medical Research under A. Neuberger in London. He came to the NCI in 1956 as Head of the Metabolism Service and rose to Director of the Division of Cancer Biology and Diagnosis in 1972. Alfred C. Ketcham (lower right) received the M.D. from the University of Rochester, interned at the Naval Medical Center in Bethesda, MD, and then trained in surgery at the United States Public Health Service Hospitals in San Francisco, CA, Seattle, WA, and Talahina, OK. He joined the NCI Surgery Branch in 1957 and was Chief from 1962 to 1974 and Clinical Director from 1970 to 1974.

Their careers were closely interwoven for 35 years during a period of marked advances in cancer treatment, supported by substantial and increasing Congressional appropriations, culminating in the appreciable increase in research funding resulting from the National Cancer Act of 1971.

Dr. Zubrod organized the clinical trials into phases I, II, and III, and served as Chairman of the Eastern Solid Tumor Group, which became a model for the current, extensive clinical trials. Appointed by then Director, Kenneth Endicott, as Scientific Director for Intramural Research, in 1961, Dr. Zubrod formed the Acute Leukemia Task Force, bringing together the country’s top scientists. Remarkable success was achieved in developing drug combinations for control of childhood leukemia and in treating Hodgkin’s disease. For his leadership, he has aptly been called the “father of chemotherapy.”

Dr. Berlin brought together in the Metabolism Service a remarkably gifted staff of highly productive young physicians, including Nobel Laureate Daniel Nathans and Medal of Science Awardee David Nathan. With the strong support of NCI Director Endicott, Drs. Zubrod and Berlin expanded the intramural programs into molecular biology and virology. Dr. Berlin, simultaneously, created a wide-ranging intramural program of the Laboratories of Molecular Biology under J. Pastan, Cell Biology under L. W. Law, Pathophysiology under P. M. Gullino, Mathematical Biology under M. Berman, and Immunodiagnosis under R. B. Herberman; he also brought Robert Goldberger, Maxine Singer, and Claude Klee to the Laboratory of Biochemistry.

Dr. Ketcham joined the NCI in 1957 and, with his surgical insight thus provided, the three worked together as a smoothly functioning team. In 1970, Dr. Ketcham succeeded Dr. Berlin as Clinical Director. He expanded cancer surgery extensively through the Clinical Associates Program.

The team dissolved in 1974 when Dr. Ketcham left to head Surgical Oncology in the Department of Surgery at the University of Miami and in the Cancer Center, now the Sylvester Comprehensive Cancer Center. Dr. Zubrod soon followed as Director of the Cancer Center at the same institution. In 1975, Dr. Berlin became the Director of the Northwestern University Medical School Cancer Center in Chicago. Cooperation among the three continued for many years and became even closer when Dr. Berlin became the Chairman of the External Advisory Board to the Sylvester Cancer Center in 1977. In 1987, Dr. Berlin joined the other two on the faculty of the University of Miami.

All three had distinguished careers, marked by many publications and leadership positions in the fields of cancer research, both in the basic and clinical realms. In addition, they have also held various editorial positions and been involved in policy-making decisions. Dr. Zubrod has retired and resides in Chevy Chase, MD. Dr. Berlin is spending a year at the NCI, and Dr. Ketcham continues as Professor of Surgery at the University of Miami.

Sidney Weinhouse